These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35904051)

  • 1. Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report.
    Imamura T; Izumida T; Hori M; Tanaka S; Kinugawa K
    J Int Med Res; 2022 Jul; 50(7):3000605221078484. PubMed ID: 35904051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis.
    Imamura T; Izumida T; Nakamura M; Kinugawa K
    Int Heart J; 2022; 63(2):408-410. PubMed ID: 35354759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort.
    Ochi Y; Kubo T; Baba Y; Sugiura K; Miyagawa K; Noguchi T; Hirota T; Hamada T; Yamasaki N; Kitaoka H
    Circ J; 2022 Jun; 86(7):1121-1128. PubMed ID: 35599003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.
    Pollak A; Falk RH
    Chest; 1993 Aug; 104(2):618-20. PubMed ID: 8339658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac amyloidosis: a review of the literature.
    de Marneffe N; Dulgheru R; Ancion A; Moonen M; Lancellotti P
    Acta Cardiol; 2022 Oct; 77(8):683-692. PubMed ID: 35852493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
    O'Meara E; McDonald M; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Grzeslo A; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk LM; Moe GW; Swiggum E; Toma M; Virani SA; Zieroth S; De S; Matteau S; Parent MC; Asgar AW; Cohen G; Fine N; Davis M; Verma S; Cherney D; Abrams H; Al-Hesayen A; Cohen-Solal A; D'Astous M; Delgado DH; Desplantie O; Estrella-Holder E; Green L; Haddad H; Harkness K; Hernandez AF; Kouz S; LeBlanc MH; Lee D; Masoudi FA; McKelvie RS; Rajda M; Ross HJ; Sussex B
    Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
    Aimo A; Vergaro G; Castiglione V; Rapezzi C; Emdin M
    Eur J Intern Med; 2020 Oct; 80():66-72. PubMed ID: 32475765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.
    Giblin GT; Cuddy SAM; González-López E; Sewell A; Murphy A; Dorbala S; Falk RH
    Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1029-1039. PubMed ID: 35274130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.
    Tini G; Cappelli F; Biagini E; Musumeci B; Merlo M; Crotti L; Cameli M; Di Bella G; Cipriani A; Marzo F; Guerra F; Forleo C; Gagliardi C; Zampieri M; Carigi S; Vianello PF; Mandoli GE; Ciliberti G; Lichelli L; Mariani D; Porcari A; Russo D; Licordari R; Ponziani A; Porto I; Perfetto F; Autore C; Rapezzi C; Sinagra G; Canepa M
    ESC Heart Fail; 2021 Aug; 8(4):3369-3374. PubMed ID: 33988312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
    Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
    Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
    Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Tafamidis on Circulating Endothelial Progenitor Cells in Patients with Transthyretin Cardiac Amyloidosis.
    Itzhaki Ben Zadok O; Leshem-Lev D; Ben-Gal T; Hamdan A; Schamroth Pravda N; Steinmetz T; Kandinov I; Ovadia I; Kornowski R; Eisen A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):489-496. PubMed ID: 34550515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
    Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
    Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic avenues in cardiac amyloidosis.
    Golatkar V; Bhatt LK
    Eur J Pharmacol; 2023 Dec; 960():176142. PubMed ID: 37866746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates for the diagnosis and management of cardiac amyloidosis.
    Gościniak P; Baron T; Milczarek S; Kostkiewicz M; Machaliński B
    Adv Clin Exp Med; 2022 Feb; 31(2):175-185. PubMed ID: 35195962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction].
    Nakayama M; Ishii A; Takeguchi F; Nakano H
    J Cardiol; 2006 Jun; 47(6):285-91. PubMed ID: 16800371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.